Clinical investigation of medicinal products for treatment of rheumatoid arthritis

  • Email
  • Help
Current effective version

Revision 2 - Adopted guideline

Revision 2 enters into effect 01/07/2018 - see below

Reference numberCPMP/EWP/556/95 Rev. 2
Published10/01/2018
Effective from01/07/2018
KeywordsRheumatoid arthritis, disease modifying anti-rheumatic drugs, clinical development, CHMP, EMA, guideline
Description

This document is intended to provide guidance on the clinical evaluation of medicinal products in the treatment of rheumatoid arthritis (RA). 

*The guideline has been formerly known as "Clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs (NSAIDs) for treatment of rheumatoid arthritis".


Document history

Revision 2 

Current version

Adopted guideline

 

 
Draft guideline
 

Draft guideline
 

Concept paper

Published: 10/01/2018
Effective from: 01/07/2018

 

Published: 04/06/2015
 

Published: 20/12/2011
 

Published: 01/02/2010

Revision 1

 

Points to considerIn operation: 01/06/2004–present


Related content


How helpful is this page?

Average rating:

 Based on 5 ratings

Add your rating:

See all ratings
1 ratings
1 ratings
1 ratings
1 ratings
1 ratings
    

Tell us more